Safety and Efficacy of Intravitreal Preservative-Free @entity2995 (Triesence) for XXXX .

@entity1 @entity2995 @entity1103 @entity1020 @entity3225
PURPOSE: To evaluate the efficacy and safety of preservative-free @entity2995 (Triesence) for the treatment of @entity1103 . METHODS: A retrospective study was conducted on @entity1 who attended a tertiary retinal clinic from June 2009 to July 2012 with @entity1103 due to various causes. @entity1 who received at least 1 intravitreal Triesence injection and completed 6 months of follow-up were recruited. Data, including best-corrected Snellen visual acuity, @entity1020 ( @entity1020 ), intraocular pressure (IOP), and adverse events (AEs), were collected at baseline, week 1, month 1, month 3, and month 6 after initiation of treatment. Snellen visual acuity was converted to visual acuity score (VAS) for statistical analysis using paired t-tests and linear regression. RESULTS: One hundred two eyes from 102 @entity1 were included in the study. Mean VAS was significantly improved at all follow-up time points compared to baseline (P <=0.002), with highest mean gain at month 1 (6.1  8.9 letters). Mean @entity1020 decreased significantly at all follow-up points compared to baseline (P <=0.0005), with the greatest reduction at week 1 (146.6  109.4    m). A total of 22 AEs were observed, and IOP elevation was the most common AE related to Triesence treatment (17/22, 77.3%). No sterile or @entity3225 was observed. CONCLUSION: Intravitreal Triesence improves visual acuity and reduces macular thickness in eyes with @entity1103 from various causes. Treatment-associated IOP elevation was manageable with antiglaucoma medications. There were no serious vision-threatening complications associated with intravitreal Triesence therapy during the study period.
